The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

Beyfortus contains the active ingredient nirsevimab-alip,* and Synagis contains palivizumab. If you have other questions about how Beyfortus and Synagis compare, talk with your child’s doctor.

Find out whether you should get the RSV vaccine, known as Abrysvo, during pregnancy and when it's recommended.

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

When Beyfortus was approved over the summer, AstraZeneca and Sanofi, the two companies that manufacture the drug, said it would be available for babies in time for RSV season this year.

The list price for Sanofi’s antibody product, Beyfortus, is $495 a dose; babies would receive one dose. The list price for the maternal vaccine is $295 a dose, which is hefty for a vaccine.

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs . Late-breaking data show infant respiratory syncytial virus (RSV) ...

Across all clinical endpoints, a single dose of Beyfortus delivered consistent and sustained efficacy against RSV disease vs placebo Beyfortus is the first preventive option approved to protect a ...